Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Huagai Capital

Founders Lu Binghui Xiaolin Xu

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 125
Average round size
info
The average size of a deal this fund participated in
$29M
Portfolio companies 108
Rounds per year 10.42
Lead investments 34
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.13
Exits 8
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Medical
  • Biotechnology
  • Pharmaceutical
  • Manufacturing
Summary

Huagai Capital is the famous VC, which was founded in 2012. The leading representative office of defined VC is situated in the Beijing. The venture was found in Asia in China.

Opposing the other organizations, this Huagai Capital works on 17 percentage points less the average amount of lead investments. The typical startup value when the investment from Huagai Capital is 500 millions - 1 billion dollars. The fund is constantly included in 2-6 investment rounds annually. Speaking about the real fund results, this VC is 56 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2019. The increased amount of exits for fund were in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Tiger Brokers, EdiGene, Songxiaocai. For fund there is a match between the location of its establishment and the land of its numerous investments - China.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Huagai Capital, startups are often financed by Sequoia Capital China, Qiming Venture Partners, Qualcomm Ventures. The meaningful sponsors for the fund in investment in the same round are ZhenFund, Tranquility Capital, Sequoia Capital China. In the next rounds fund is usually obtained by Lilly Asia Ventures, IDG Capital, Green Pine Capital Partners.

This organization was formed by Lu Binghui, Xu Xiaolin. Besides them, we counted 2 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Huagai Capital:
Typical Co-investors
Huagai Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Huagai Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Baijun Biotech

Biopharma
Pharmaceutical
Service Industry
19 Sep 2024 -

Ai Sensing Technology

16 May 2024 Guangdong, Tianjin, China

Micro Interventional

18 Mar 2024 Hangzhou, Zhejiang, China

Cybernetics

Advanced Materials
Internet of Things
Manufacturing
26 Feb 2024 Haidian, Beijing, China

Utarn Technology

Artificial Intelligence
Robotics
19 Feb 2024 Shangcheng District, Zhejiang, China

Bowang Pharmaceutical

Biotechnology
Product Research
$46M01 Nov 2023 Jiading, Shanghai, China

Leo Summit

Biotechnology
Life Science
Manufacturing
Medical
08 Sep 2023 Changping, Beijing, China

Leaf Biotech

Biotechnology
Pharmaceutical
Sales
$30M25 Jun 2023 Hefei, Anhui, China

Dingzhi Biotech

Health Care
Pet
Veterinary
21 Jun 2023 Daxing, Beijing, China
News
PAQ Therapeutics Raises $30M in Series A Funding

– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Huagai Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 125
Average round size 29M
Rounds per year 10.42
Peak activity year 2021
Lead investments 34
Follow on index 0.13
Exits 8
Group Appearance index 0.78

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Baijun Biotech

Biopharma
Pharmaceutical
Service Industry
19 Sep 2024 -

Ai Sensing Technology

16 May 2024 Guangdong, Tianjin, China

Micro Interventional

18 Mar 2024 Hangzhou, Zhejiang, China

Cybernetics

Advanced Materials
Internet of Things
Manufacturing
26 Feb 2024 Haidian, Beijing, China

Utarn Technology

Artificial Intelligence
Robotics
19 Feb 2024 Shangcheng District, Zhejiang, China

Bowang Pharmaceutical

Biotechnology
Product Research
$46M01 Nov 2023 Jiading, Shanghai, China

Leo Summit

Biotechnology
Life Science
Manufacturing
Medical
08 Sep 2023 Changping, Beijing, China

Leaf Biotech

Biotechnology
Pharmaceutical
Sales
$30M25 Jun 2023 Hefei, Anhui, China

Dingzhi Biotech

Health Care
Pet
Veterinary
21 Jun 2023 Daxing, Beijing, China
Crunchbase icon

Content report

The following text will be sent to our editors: